天弘中证医药100A（001550）基金经理为贺雨轩。 截至发稿，贺雨轩累计任职时间4年225天，现任基金资产总规模112.26亿元，任职期间最佳基金回报 115.83%， 任职期间最差基金回报-61.43%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，天弘基金旗下1只基金重仓奕瑞科技。天弘中证医药100A（001550）四季度持有股数13.4万 股，占基金净值比例为0.99%，位居第九大重仓股。根据测算，今日浮盈赚取约20.24万元。连续5天上 涨期间浮盈赚取164.02万元。 天弘中证医药100A（001550）成立日期2015年6月30日，最新规模6.92亿。今年以来收益2.73%，同类 排名2980/5580；近一年收益10.73%，同类排名3734/4290；成立以来亏损19.61%。 2月9日，奕瑞科技涨1.24%，截至发稿，报123.58元/股，成交3.77亿元，换手率1.54%，总 ...

Core Viewpoint - Yirui Technology (688301.SH), a manufacturer of digital X-ray detectors, achieved record high performance in 2025, with significant revenue and profit growth driven by stable growth in its digital X-ray detector business and substantial growth in comprehensive solutions and core components [2][4]. Financial Performance - In 2025, the company reported revenue of 2.299 billion yuan, a year-on-year increase of 25.53% - The net profit attributable to shareholders reached 661 million yuan, up 42.15% - The net profit after deducting non-recurring gains and losses was 627 million yuan, reflecting a growth of 42.89% [2][4]. Market Position - Yirui Technology holds a leading position in the global market for digital X-ray detectors, with a market share of 19.83% in 2024, up from 16.46% in 2021 [3]. - The company has consistently ranked first in market share within China for digital X-ray detectors [3]. Employee Incentives - The company is implementing a multi-tiered incentive system to enhance talent development and bind the core team, promoting long-term growth [6]. - A 2026 employee stock ownership plan has been proposed, with an initial cap of 150 participants and a funding limit of 100 million yuan, linked to performance targets based on 2025 net profit [6][7]. Strategic Investments - In October 2025, Yirui Technology raised 1.16 billion yuan through a private placement to fund projects related to X-ray vacuum devices and comprehensive solutions [5]. - The total assets of the company reached 12.79 billion yuan by the end of 2025, a 40.81% increase from the previous year [5]. Subsidiary Development - Yirui Hefei, a wholly-owned subsidiary, is set to introduce strategic investors through a 500 million yuan capital increase, enhancing its financial strength and operational scale [8][9]. - The introduction of local state-owned investors is expected to deepen strategic cooperation and improve the subsidiary's market competitiveness [8].

1月28日，奕瑞科技跌2.85%，成交额2.73亿元。两融数据显示，当日奕瑞科技获融资买入额2057.02万 元，融资偿还1725.17万元，融资净买入331.85万元。截至1月28日，奕瑞科技融资融券余额合计7.32亿 元。 融资方面，奕瑞科技当日融资买入2057.02万元。当前融资余额7.30亿元，占流通市值的3.20%，融资余 额超过近一年90%分位水平，处于高位。 截至9月30日，奕瑞科技股东户数8011.00，较上期增加14.61%；人均流通股24992股，较上期减少 12.74%。2025年1月-9月，奕瑞科技实现营业收入15.49亿元，同比增长14.22%；归母净利润4.71亿元， 同比增长20.61%。 分红方面，奕瑞科技A股上市后累计派现7.89亿元。近三年，累计派现5.57亿元。 机构持仓方面，截止2025年9月30日，奕瑞科技十大流通股东中，香港中央结算有限公司位居第九大流 通股东，持股380.20万股，为新进股东。华宝中证医疗ETF（512170）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，奕瑞科技1月28日融券偿还600.00股，融券卖出3800.00股，按当日收盘价计算， ...

业绩增长主要数字化X线探测器业务平稳增长，综合解决方案及核心部件业务大幅增长所致。 智通财经APP讯，奕瑞科技(688301.SH)披露2025年度业绩快报，2025年度实现营业收入22.99亿元，同 比增长25.53%;归属于母公司所有者的净利润6.61亿元，同比增长42.15%。 ...

归属于母公司所有者的净利润较上年同期增长42.15%，归属于母公司所有者的扣除非经常性损益的净 利润同比增长42.89%，主要原因系2025年营业收入较上年持续提升，同时公司继续专注于精益生产和 管理，毛利率和净利率保持在较高水准，相关利润指标较上年有大幅增长。 格隆汇1月28日丨奕瑞科技(688301.SH)公布2025年度业绩快报，报告期内，公司实现营业收入22.99亿 元，同比增加25.53%；实现归属于母公司所有者的净利润6.61亿元，同比增加42.15%，主要数字化X线 探测器业务平稳增长，综合解决方案及核心部件业务大幅增长所致；实现归属于母公司所有者的扣除非 经常性损益的净利润6.27亿元，同比增加42.89%。 ...

格隆汇1月28日丨奕瑞科技(688301.SH)公布2025年度业绩快报，报告期内，公司实现营业收入22.99亿 元，同比增加25.53%；实现归属于母公司所有者的净利润6.61亿元，同比增加42.15%，主要数字化X线 探测器业务平稳增长，综合解决方案及核心部件业务大幅增长所致；实现归属于母公司所有者的扣除非 经常性损益的净利润6.27亿元，同比增加42.89%。 归属于母公司所有者的净利润较上年同期增长42.15%，归属于母公司所有者的扣除非经常性损益的净 利润同比增长42.89%，主要原因系2025年营业收入较上年持续提升，同时公司继续专注于精益生产和 管理，毛利率和净利率保持在较高水准，相关利润指标较上年有大幅增长。 ...

Core Viewpoint - Yirui Technology is positioned as a leading domestic X-ray detector manufacturer, benefiting from a recovery in medical tenders and a resurgence in lithium battery capital expenditures, indicating a turning point in its main business performance [1] Group 1: Company Overview - Yirui Technology is one of the few global manufacturers that master all major core technologies in digital X-ray detectors [1] - The company has entered the supply chains of global giants such as GE, Siemens, and Philips, continuously leading domestic substitution [1] - The company maintains strong profitability due to its comprehensive solution offerings and vertical supply chain integration, which create core advantages under high technical barriers [1] Group 2: Growth Potential - The binding with Shiya Technology allows Yirui Technology to enter the high-growth AI glasses market, which is expected to bring new growth drivers for the company [1] - The OLED backplane processing business is anticipated to accelerate performance contributions [1] Group 3: Investment Rating - The initial coverage of Yirui Technology has been given a "strong buy" investment rating [1]

Investment Rating - The report gives a "Strong Buy" investment rating for the company [1][11]. Core Insights - The company is a leading domestic X-ray detector manufacturer, expected to benefit from a recovery in medical tenders and a resurgence in capital expenditure in the lithium battery sector, marking a turning point in its main business performance [2][8]. - The company is entering the high-growth AI glasses market through a partnership with Visionary Technology, which is anticipated to open new growth avenues [3][11]. Company Overview - The company is recognized as a leader in the domestic X-ray detector market, with a projected global market share of 20% by 2024 [18]. - It specializes in digital X-ray detectors, high-voltage generators, combination X-ray sources, and tubes, with applications spanning medical, industrial, and dental fields [18][19]. Main Business - The company is transitioning from a single supplier of X-ray detectors to a comprehensive supplier of X-ray solutions, enhancing product value and customer loyalty [8][27]. - Short-term recovery is expected due to improved downstream demand, with a projected revenue growth of 20% in 2025 [10][11]. - Long-term growth is driven by expanding product offerings, industry applications, and market penetration, with a focus on increasing overseas business, which is expected to account for 34% of revenue by mid-2025 [8][11]. New Business Ventures - The company is entering the high-growth AI glasses sector, leveraging its capabilities in OLED micro-displays through a partnership with Visionary Technology [3][9]. - The global XR device shipment is projected to grow significantly, with a CAGR of 55.5% from 2025 to 2029, indicating a robust market opportunity [8][11]. Financial Data and Valuation - Revenue projections for 2025, 2026, and 2027 are estimated at 22.01 billion, 34.56 billion, and 44.54 billion yuan, respectively, with corresponding net profits of 6.25 billion, 7.87 billion, and 10.08 billion yuan [10][11]. - The company maintains a strong financial position with a return on equity (ROE) of 9.0% and a debt-to-asset ratio of 46.4% [4].

Core Viewpoint - Yirui Technology's stock has shown a positive trend with a year-to-date increase of 8.66% and a recent uptick of 2.02% on January 6, 2025, indicating strong market interest and performance in the medical device sector [1]. Group 1: Stock Performance - As of January 6, 2025, Yirui Technology's stock price reached 109.87 yuan per share, with a trading volume of 2.24 billion yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 23.232 billion yuan [1]. - The stock has experienced a 6.67% increase over the last five trading days and an 8.41% increase over the last 20 trading days, while it has seen a decline of 5.01% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yirui Technology reported a revenue of 1.549 billion yuan, reflecting a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million yuan, which is a 20.61% increase compared to the previous year [2]. - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Yirui Technology increased to 8,011, marking a 14.61% rise, while the average number of circulating shares per person decreased by 12.74% to 24,992 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant holding 3.802 million shares, while Huabao Zhongzheng Medical ETF has exited the list [3]. Group 4: Business Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and service of digital X-ray detectors, with the main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with various concepts including medical devices, mid-cap stocks, margin financing, security, and share buybacks [1].

Group 1 - The core business of Yirui Technology includes the research, production, sales, and service of digital X-ray detectors, with the main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service revenue (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] - As of December 31, Yirui Technology's stock price decreased by 1.05%, trading at 101.24 yuan per share, with a total market capitalization of 21.407 billion yuan [1] Group 2 - Southern Fund has a significant holding in Yirui Technology through its Southern SSE STAR Market Composite ETF Linked A (023731), which ranks as the fifth largest holding with 28 shares [2] - The Southern SSE STAR Market Composite ETF Linked A has a total scale of 97.6034 million yuan and has achieved a return of 38.76% since its inception [2] - The fund managers, Yang Kaining and Pan Shuiyang, have delivered varying performance, with Yang achieving a best return of 75% and Pan achieving a best return of 110.42% during their respective tenures [2]